Predictive Oncology CEO Raymond Vennare and Cvergenx CEO Javier Torres-Roca join Natalie Stoberman to share their new partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence.
Vennare says the objective of this collaboration will be to leverage Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities with the Cvergenx precision genomics radiation therapy platform.